Leo Cancer Care announced the close of an oversubscribed $65 million Series D financing round. The round was led by Yu Galaxy, with new investor Eventide Asset Management joining alongside continued support from existing investors.
Leo Cancer Care is developing cancer imaging and treatment systems designed around the body’s natural upright position. The company’s integrated upright platform spans proton therapy, photon therapy, and imaging.
The funding will be used to scale manufacturing, accelerate commercial deployment, and continue clinical and product development. Leo Cancer Care said its unified upright architecture supports cancer care from diagnosis and planning through treatment.
The company’s platform is based on the idea that the human body spends most of its life upright. Leo Cancer Care said growing research indicates upright positioning may support more consistent anatomical positioning and organ stability compared with conventional lying-down treatment approaches.
At the center of the platform is an upright imaging system that is FDA-cleared. The company also plans future applications across radiology, in addition to treatment planning and delivery.
Leo Cancer Care’s Marie platform recently reached a major milestone at Stanford Medicine. On June 4, 2026, Stanford Medicine delivered the world’s first compact upright proton therapy treatment using the platform, treating a 7-year-old child with a complex brain tumor.
The Marie platform fixes the radiation beam and gently rotates the seated patient instead of rotating a multi-ton gantry. Leo Cancer Care said this enables a proton therapy treatment room about 5 times smaller than a conventional gantry-based system, based on actual facility drawings.
The smaller footprint could allow proton therapy to be installed within existing radiotherapy vaults. Leo Cancer Care said this could help bring advanced cancer care closer to more patients and communities.
Leading institutions are already adopting the upright approach. Dana-Farber Cancer Institute and McLaren Health Care are among the organizations bringing Leo Cancer Care’s upright platform into their programs.
Alongside the financing, Leo Cancer Care has entered a major strategic partnership with an international healthcare company. Details of the collaboration are expected to be announced separately in the coming weeks.
KEY QUOTES:
“What began as a vision to improve radiation therapy has evolved into something much broader. For decades, the industry has tried to lower the cost of cancer care by making equipment cheaper and stripping out capability. Our treatment approach is the opposite — to reimagine how care is delivered, designed around the patient rather than the machine, so advanced treatment can reach communities that never had access before, without compromising quality. This financing lets us accelerate that platform strategy across proton, photon and imaging.”
Stephen Towe, CEO and Co-Founder of Leo Cancer Care
“Leo Cancer Care is poised to revolutionize cancer treatment in more than ten countries, with many installations the first in their region or country. The upright radiotherapy and radiology technologies Leo has pioneered are lowering the cost and shortening the time of cancer treatment, and providing options that did not exist before for pediatric patients and patients of larger body size. The result is a dramatic expansion of access to both radiotherapy and diagnostic radiology for a far larger population.”
PR Yu, Founder of Yu Galaxy
